Alterola Biotech Stock Performance
| ABTI Stock | USD 0.01 0 25.00% |
Alterola Biotech holds a performance score of 5 on a scale of zero to a hundred. The firm shows a Beta (market volatility) of 0.57, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, Alterola Biotech's returns are expected to increase less than the market. However, during the bear market, the loss of holding Alterola Biotech is expected to be smaller as well. Use Alterola Biotech maximum drawdown, accumulation distribution, relative strength index, as well as the relationship between the semi variance and day typical price , to analyze future returns on Alterola Biotech.
Risk-Adjusted Performance
5 of 100
Weak | Strong |
Modest
Compared to the overall equity markets, risk-adjusted returns on investments in Alterola Biotech are ranked lower than 5 (%) of all global equities and portfolios over the last 90 days. Despite fairly unsteady basic indicators, Alterola Biotech demonstrated solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 63.8 K | |
| Free Cash Flow | 44.3 K |
Alterola |
Alterola Biotech Relative Risk vs. Return Landscape
If you would invest 0.61 in Alterola Biotech on September 1, 2024 and sell it today you would lose (0.11) from holding Alterola Biotech or give up 18.03% of portfolio value over 90 days. Alterola Biotech is currently generating 1.5838% in daily expected returns and assumes 20.8694% risk (volatility on return distribution) over the 90 days horizon. In different words, most equities are less risky than Alterola, and most traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Alterola Biotech Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Alterola Biotech's investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as Alterola Biotech, and traders can use it to determine the average amount a Alterola Biotech's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0759
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ABTI | |||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 20.87 actual daily | 96 96% of assets are less volatile |
Expected Return
| 1.58 actual daily | 31 69% of assets have higher returns |
Risk-Adjusted Return
| 0.08 actual daily | 5 95% of assets perform better |
Based on monthly moving average Alterola Biotech is performing at about 5% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Alterola Biotech by adding it to a well-diversified portfolio.
Alterola Biotech Fundamentals Growth
Alterola Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Alterola Biotech, and Alterola Biotech fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Alterola Pink Sheet performance.
| Return On Equity | -1.27 | |||
| Return On Asset | -0.67 | |||
| Current Valuation | 68.08 M | |||
| Shares Outstanding | 807.05 M | |||
| Price To Book | 6.29 X | |||
| EBITDA | (6.47 M) | |||
| Cash And Equivalents | 61.54 K | |||
| Total Debt | 251.18 K | |||
| Debt To Equity | 0.02 % | |||
| Book Value Per Share | 0.01 X | |||
| Cash Flow From Operations | 44.34 K | |||
| Earnings Per Share | (0.01) X | |||
| Total Asset | 12.13 K | |||
About Alterola Biotech Performance
By evaluating Alterola Biotech's fundamental ratios, stakeholders can gain valuable insights into Alterola Biotech's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Alterola Biotech has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Alterola Biotech has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
Alterola Biotech, Inc., a pharmaceutical company, engages in the development of cannabinoid and cannabinoid-like molecules. It focuses on the development of regulated human and animal health pharmaceuticals and regulated food products production of active pharmaceutical ingredients and food-grade ingredients and formulation and drug delivery for improved bioavailability, solubility, and stability. Alterola Biotech is traded on OTC Exchange in the United States.Things to note about Alterola Biotech performance evaluation
Checking the ongoing alerts about Alterola Biotech for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Alterola Biotech help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Alterola Biotech is way too risky over 90 days horizon | |
| Alterola Biotech has some characteristics of a very speculative penny stock | |
| Alterola Biotech appears to be risky and price may revert if volatility continues | |
| Alterola Biotech has high likelihood to experience some financial distress in the next 2 years | |
| Alterola Biotech currently holds 251.18 K in liabilities with Debt to Equity (D/E) ratio of 0.02, which may suggest the company is not taking enough advantage from borrowing. Alterola Biotech has a current ratio of 0.1, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Alterola Biotech until it has trouble settling it off, either with new capital or with free cash flow. So, Alterola Biotech's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Alterola Biotech sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Alterola to invest in growth at high rates of return. When we think about Alterola Biotech's use of debt, we should always consider it together with cash and equity. | |
| Net Loss for the year was (6.47 M) with profit before overhead, payroll, taxes, and interest of 0. |
- Analyzing Alterola Biotech's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Alterola Biotech's stock is overvalued or undervalued compared to its peers.
- Examining Alterola Biotech's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Alterola Biotech's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Alterola Biotech's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Alterola Biotech's pink sheet. These opinions can provide insight into Alterola Biotech's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Alterola Pink Sheet analysis
When running Alterola Biotech's price analysis, check to measure Alterola Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Alterola Biotech is operating at the current time. Most of Alterola Biotech's value examination focuses on studying past and present price action to predict the probability of Alterola Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Alterola Biotech's price. Additionally, you may evaluate how the addition of Alterola Biotech to your portfolios can decrease your overall portfolio volatility.
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing |